MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Derma Sciences sales jump 16 percent
Derma Sciences Inc. (NSDQ:DSCI) reported losses of $347,198, or 5 cents per diluted share, on sales of $15.3 million during the three months ended Dec. 31, 2010. That compares with profits $843, or less than 1 cent per diluted share, on sales of $13.6 million during the same period in 2009.
Full-year losses were $2.4 million, or 39 cents per share, on sales of $56.5 million. That compares with losses of $1.3 million, or 25 cents per share, on sales of $48.5 million in 2009.
Read more
Bacterin losses widen more than 340 percent
Bacterin International Holdings Inc. (NYSE Amex:BONE) reported losses of $5.5 million, or 15 cents per basic share, on sales of $5.3 million during the three months ended Dec. 31, 2010. That compares with losses of $1.6 million, or 6 cents per basic share, on sales of $2.2 million during the same period in 2009.
Full-year losses were $18.2 million, or 57 cents per share, on sales of $15.4 million. That compares with losses of $4.1 million, or 16 cents per share, on sales of $7.4 million in 2009.
Read more
Response Genetics losses halve
Response Genetics Inc. (NSDQ:RGDX) reported losses of $1.1 million, or 6 cents per basic share, on sales of $6.4 million during the three months ended Dec. 31. That compares with losses of $1.7 million, or 11 cents per diluted share, on sales of $3.4 during the same period in 2009.
Full-year losses were $4.7 million, or 26 cents per share, on sales of $21.3 million. That compares with losses of $9.3 million, or 70 cents per share, on sales of $9.1 million in 2009.
Read more
Nephros losses remain unchanged after small sales bump
Nephros Inc. (OTC:NEPHD) reported losses of $665,000, or 32 cents per diluted share, on sales of $517,000 during the three months ended Dec. 31, 2010. That compares with losses of $483,000, or 25 cents per diluted share, on sales of $792,000 during the same period in 2009.
Full-year losses were $1.9 million, or 93 cents per share, on sales of $2.9 million. That compares with losses of $2.0 million, or $1.06 per share, on sales of $2.7 million in 2009.
Read more
Guided Therapeutics losses ease after sales double
Guided Therapeutics Inc. (OTC:GTHP) reported losses of $280,000, or 1 cent per diluted share, on sales of $1.1 million during the three months ended Dec. 31, 2010. That compares with losses of $1.5 million, or 8 cents per diluted share, on sales of $550,000 during the same period in 2009.
Full-year losses were $4.5 million, or 12 cents per share, on sales of $3.4 million. That compares with losses of $6.4 million, or 38 cents per share, on sales of $1.6 million in 2009.
Read more
Elbit sales push company into the black
Elbit Imaging Ltd. (NSDQ:EMITF) reported profits of $19.5 million on sales of $111.9 million during the year ended Dec. 31, 2010. That compares with losses of $190.6 million on no revenue in 2009.
Read more
Spherix losses ease despite unchanged sales
Spherix Inc. (NSDQ:SPEX) reported losses of $7.7 million, or 43 cents per diluted share, on sales of $1.4 million during the year ended Dec. 31, 2010. That compares with losses of $9.1 million, or 62 cents per diluted share, on sales of $1.4 million in 2009.
Read more
NeurogesX losses double
NeurogesX Inc. (NSDQ:NGSX) reported losses of $12.4 million, or 69 cents per diluted share, on sales of $458,000 during the three months ended Dec. 31, 2010. That compares with losses $5.1 million, or 29 cents per diluted share, on no revenues during the same period in 2009.
Full-year losses were $44.5 million, or $2.51 cents per share, on sales of $688,000. That compares with losses of $21.9 million, or $1.24 per share, on no revenues in 2009.
Read more
